1. Home
  2. CGBD vs RAPP Comparison

CGBD vs RAPP Comparison

Compare CGBD & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGBD
  • RAPP
  • Stock Information
  • Founded
  • CGBD 2012
  • RAPP 2022
  • Country
  • CGBD United States
  • RAPP United States
  • Employees
  • CGBD N/A
  • RAPP N/A
  • Industry
  • CGBD Finance: Consumer Services
  • RAPP
  • Sector
  • CGBD Finance
  • RAPP
  • Exchange
  • CGBD Nasdaq
  • RAPP Nasdaq
  • Market Cap
  • CGBD 909.7M
  • RAPP 844.6M
  • IPO Year
  • CGBD 2017
  • RAPP 2024
  • Fundamental
  • Price
  • CGBD $18.35
  • RAPP $13.27
  • Analyst Decision
  • CGBD Hold
  • RAPP Strong Buy
  • Analyst Count
  • CGBD 4
  • RAPP 4
  • Target Price
  • CGBD $16.25
  • RAPP $37.33
  • AVG Volume (30 Days)
  • CGBD 268.8K
  • RAPP 112.9K
  • Earning Date
  • CGBD 02-25-2025
  • RAPP 02-10-2025
  • Dividend Yield
  • CGBD 7.58%
  • RAPP N/A
  • EPS Growth
  • CGBD 29.39
  • RAPP N/A
  • EPS
  • CGBD 1.72
  • RAPP N/A
  • Revenue
  • CGBD $238,921,000.00
  • RAPP N/A
  • Revenue This Year
  • CGBD N/A
  • RAPP N/A
  • Revenue Next Year
  • CGBD $4.63
  • RAPP N/A
  • P/E Ratio
  • CGBD $10.64
  • RAPP N/A
  • Revenue Growth
  • CGBD 1.68
  • RAPP N/A
  • 52 Week Low
  • CGBD $14.76
  • RAPP $12.10
  • 52 Week High
  • CGBD $18.74
  • RAPP $29.74
  • Technical
  • Relative Strength Index (RSI)
  • CGBD 60.10
  • RAPP N/A
  • Support Level
  • CGBD $17.31
  • RAPP N/A
  • Resistance Level
  • CGBD $18.56
  • RAPP N/A
  • Average True Range (ATR)
  • CGBD 0.29
  • RAPP 0.00
  • MACD
  • CGBD 0.01
  • RAPP 0.00
  • Stochastic Oscillator
  • CGBD 83.20
  • RAPP 0.00

About CGBD Carlyle Secured Lending Inc.

Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.

About RAPP Rapport Therapeutics Inc. Common Stock

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Share on Social Networks: